BridgeBio Pharma股份在Q4收入强劲增长上猛增9.3%,尽管在遗传疾病和癌症药物进步的驱动下损失惨重。 BridgeBio Pharma shares jumped 9.3% on strong Q4 revenue growth despite a loss, driven by genetic disease and cancer drug progress.

BridgeBio Pharma(BBIO)股份在报告Q4年收入1.5418亿美元(比同年增加2 521%,超过估计数)之后,在星期二上升,增加9.3%至71.76美元,尽管每股损失1.0美元,但预期损失为2.5美元。 BridgeBio Pharma (BBIO) shares rose on Tuesday, gaining 9.3% to $71.76, after reporting Q4 revenue of $154.18 million—up 2,521% year-over-year and exceeding estimates—despite a $1.00 per share loss, missing expectations by $0.25. 分析师保持"中等买入"的共识评级,平均1年价格目标为82.50美元,而摩根大通将其目标提高到94.00美元,而华盛顿银行将其目标升级为"买入"以100美元的目标. Analysts maintain a "Moderate Buy" consensus rating with an average 1-year price target of $82.50, while JPMorgan raised its target to $94.00 and HC Wainwright upgraded to "Buy" with a $100.00 target. 该公司设在帕洛阿尔托,侧重于遗传疾病和癌症治疗,多个输油管候选者正在取得进展。 The company, based in Palo Alto, focuses on genetic disease and cancer therapies, with multiple pipeline candidates advancing. 上个季度内幕销售总额达1 610万美元,所有权减少到18.20%,而机构持有量仍为99.85%。 Insider selling totaled $16.1 million in the past quarter, reducing ownership to 18.20%, while institutional holdings remain at 99.85%.